Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
HTG Molecular Diagnostics developed and commercialized proprietary next-generation sequencing-based platforms—primarily the EdgeSeq system—for high-throughput gene expression profiling from challenging samples such as FFPE tissue. Their products enabled biomarker discovery and translational research across oncology and immunology. The company filed for bankruptcy in June 2023 after years of declining revenue.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on HTG Molecular Diagnostics.